Long-term organ culture of keloid disease tissue

Experimental Dermatology

Volumn 21, Issue 5, 2012, Pages 376-381

  Bagabir, Rania ^a   Syed, Farhatullah ^a   Paus, Ralf ^a,b   Bayat, Ardeshir ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Dulbecco's modified Eagle's medium (DMEM); Enzyme linked immunosorbent assay (ELISA); Keloid disease; Organ culture; Terminal deoxynucleotide transferase mediated dUTP nick end labelling (TUNEL); William's E medium (WE)

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; DEXAMETHASONE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; LANGERIN; LEUKOCYTE ELASTASE; TRYPTASE; VIMENTIN;

ADOLESCENT; ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; KELOID; MALE; NICK END LABELING; PHENOTYPE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; SKIN BIOPSY; SKIN CULTURE; STAINING;

ACNE KELOID; ADOLESCENT; ADULT; AGED; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, CD31; BIOPSY; COLLAGEN; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN CULTURE TECHNIQUES; PHENOTYPE; SKIN; YOUNG ADULT;

EID: 84859915882     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2012.01476.x     Document Type: Review

References (44)

1. Brown B C, McKenna S P, Solomon M et al. The patient-reported impact of scars measure: development and validation. Plast Reconstr Surg 2010: 125: 1439-1449.
2. Seifert O, Mrowietz U. Keloid scarring: bench and bedside. Arch Dermatol Res 2009: 301: 259-272.
3. Bock O, Schmid-Ott G, Malewski P et al. Quality of life of patients with keloid and hypertrophic scarring. Arch Dermatol Res 2006: 297: 433-438.
4. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997: 37: 755-757.
5. Studdiford J, Stonehouse A, Altshuler M et al. The management of keloids: hands-on versus hands-off. J Am Board Fam Med 2008: 21: 149-152.
6. Seifert O, Bayat A, Geffers R et al. Identification of unique gene expression patterns within different lesional sites of keloids. Wound Repair Regen 2008: 16: 254-265.
7. Lim I J, Phan T-T, Bay B-H et al. Fibroblasts cocultured with keloid keratinocytes: Normal fibroblasts secrete collagen in a keloidlike manner. Am J Physiol Cell Physiol 2002: 283: C212-C222.
8. Sebastian A, Syed F, Perry D et al. Acceleration of cutaneous healing by electrical stimulation: degenerate electrical waveform down-regulates inflammation, up-regulates angiogenesis and advances remodeling in temporal punch biopsies in a human volunteer study. Wound Repair Regen 2011: 19: 693-708.
9. Ranzato E, Martinotti S, Volante A et al. Platelet lysate modulates MMP-2 and MMP-9 expression, matrix deposition and cell-to-matrix adhesion in keratinocytes and fibroblasts. Exp Dermatol 2011: 20: 308-313.
10. Abbott A. Cell culture: Biology's new dimension. Nature 2003: 424: 870-872.
11. Sato M, Ishikawa O, Miyachi Y. Distinct patterns of collagen gene expression are seen in normal and keloid fibroblasts grown in three-dimensional culture. Br J Dermatol 1998: 138: 938-943.
12. Butler P D, Ly D P, Longaker M T et al. Use of organotypic coculture to study keloid biology. Am J Surg 2008: 195: 144-148.
13. Craig S S, DeBlois G, Schwartz L B. Mast cells in human keloid, small intestine, and lung by an immunoperoxidase technique using a murine monoclonal antibody against tryptase. Am J Surg 1986: 124: 427-435.
14. Boyce D E, Ciampolini J, Ruge F et al. Inflammatory cell subpopulations in keloid scars. Br J Plast Surg 2001: 54: 511-516.
15. Shaker S A, Ayuob N N, Hajrah N H. Cell talk: a phenomenon observed in the keloid scar by immunohistochemical study. Appl Immunohistochem Mol Morphol 2011: 19: 153.
16. Shih B, Garside E, McGrouther D A et al. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen 2010: 18: 139-153.
17. Duong H S, Zhang Q, Kobi A et al. Assessment of morphological and immunohistological alterations in long-term keloid skin explants. Cells Tissues Organs 2005: 181: 89-102.
18. Lu Z, Hasse S, Bodo E et al. Towards the development of a simplified long term organ culture method for human scalp skin and its appendages under serum free conditions. Exp Dermatol 2007: 16: 37-44.
19. Syed F, Ahmadi E, Iqbal S A et al. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol 2010: 164: 83-96.
20. Duc Ql, Breetveld M, Middelkoop E et al. A cytotoxic analysis of antiseptic medication on skin substitutes and autograft. Br J Dermatol 2007: 157: 33-40.
21. Chatterjee A, Babu R J, Klausner M et al. In vitro and in vivo comparison of dermal irritancy of jet fuel exposure using EpiDerm(TM) (EPI-200) cultured human skin and hairless rats. Toxicol Lett 2006: 167: 85-94.
22. Foitzik K, Krause K, Conrad F et al. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 2006: 168: 748-756.
23. Bagabir R A, Syed F, Rautemaa R et al. Up-regulation of toll-like receptors (TLR) 6, 7 and 8 IN Keloid SCARS: does keloid disease reflect an abnormal innate immune response to viral infection? J Invest Dermatol 2011: 131: 2128-2130.
24. Kloepper J E, Sugawara K, Al Nuaimi Y et al. Methods in hair research: how to objectively distinguish between anagen and catagen in human hair follicle organ culture. Exp Dermatol 2010: 19: 305-312.
25. Verhaegen P, van Zuijlen P P M, Pennings N M et al. Differences in collagen architecture between keloid, hypertrophic scar, normotrophic scar, and normal skin: an objective histopathological analysis. Wound Repair Regen 2009: 17: 649-656.
26. Ala-Kokko L, Rintala A, ER S. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures. J Invest Dermatol 1987: 89: 238-244.
27. Herovici C. Polychrome stain for differentiating precollagen from collagen. Stain Technol 1963: 38: 204-206.
28. Uitto J. IL-6 signaling pathway in keloids: a target for pharmacologic intervention? J Invest Dermatol 2007: 127: 6-8.
29. Park G, Yoon B S, Moon J-H et al. Green tea polyphenol epigallocatechin-3-gallate suppresses collagen production and proliferation in keloid fibroblasts via inhibition of the STAT3-signaling pathway. J Invest Dermatol 2008: 128: 2429-2441.
30. Chung H J, Steplewski A, Chung K Y et al. Collagen fibril formation. J Biol Chem 2008: 283: 25879-25886.
31. Wu W-S, Wang F-S, Yang K D et al. Dexamethasone induction of keloid regression through effective suppression of VEGF expression and keloid fibroblast proliferation. J Invest Dermatol 2006: 126: 1264-1271.
32. Zhang Q, Kelly A P, Wang L et al. Green tea extract and (-)-epigallocatechin-3-Gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K//Akt signaling pathways. J Invest Dermatol 2006: 126: 2607-2613.
33. Tuan T L Z J, Sun B, Nichter L S et al. Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts. J Invest Dermatol 1996: 106: 1007-1011.
34. Smith J C, Boone B E, Opalenik S R et al. Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2007: 128: 1298-1310.
35. Lee Y S, Vijayasingam S. Mast cells and myofibroblasts in keloid: a light microscopic, immunohistochemical and ultrastructural study. Ann Acad Med Singapore 1995: 24: 902-905.
36. Mukherjee A, Dey T K, Saha K C. Tissue mast cells in keloidal scars. Indian J Dermatol 1981: 26: 7-10.
37. Smith C J, Smith J C, Finn M C. The possible role of mast cells (allergy) in the production of keloid and hypertrophic scarring. J Burn Care Res 1987: 8: 126-131.
38. Ong C T, Khoo Y T, Tan E K et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007: 211: 95-108.
39. Zhang G Y, Yi C G, Li X et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res 2008: 300: 177-184.
40. Iqbal S A, Syed F, McGrouther D A et al. Differential distribution of haematopoietic and nonhaematopoietic progenitor cells in intralesional and extralesional keloid: do keloid scars provide a niche for nonhaematopoietic mesenchymal stem cells? Br J Dermatol 2010: 162: 1377-1383.
41. Khoo Y T, Ong C T, Mukhopadhyay A et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006: 208: 336-343.
42. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Investig Dermatol 1996: 106: 729-733.
43. Durani P, Bayat A. Levels of evidence for the treatment of keloid disease. J plast Reconstr Aesthet Surg 2008: 61: 4-17.
44. Urioste S S, Arndt K A, Dover J S. Keloids and hypertrophic scars: review and treatment strategies. Semin Cutan Med Surg, 1999: 18: 159-171.In: Elsevier.